Short-acting GLP-1 receptor agonists include exenatide (Byetta, with limited US availability) and lixisenatide (Adlyxin, discontinued in the US market)
That data may never exist unless a pharmaceutical company pursues regulatory approval for a BPC-157 derivative, which is unlikely given the peptide's lack of patent protection
In animal models, the elevated TMAO levels were significantly related to tubulointerstitial fibrosis and collagen deposition in the kidney and TMAO was demonstrated to increase in kidney injury molecule-1, phosphorylation of Smad3 (Tang et al., 2015b)
Using simple sterile water would mean the vial is only safe for a single use, as any introduction of a needle carries the risk of contamination that can then proliferate in the solution
PMID: 8462024
The effects of BPC 157 can vary by person, and common side effects are rare but possible